Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Francesca Jackson-Spence, MBChB, Barts Cancer Centre, London, UK, provides an overview of the Phase III SAMETA trial (NCT03091192), a randomized study evaluating the combination of savolitinib and durvalumab in patients with advanced papillary renal cell carcinoma. Enrollment has completed and the results of this trial are anticipated. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.